Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis

Margreke J. E. Brill,Elin M. Svensson,Mishal Pandie,Gary Maartens,Mats O. Karlsson

International Journal of Antimicrobial Agents（2017）

引用 39|浏览4

暂无评分

摘要

•LPV/r increases bedaquiline exposure 2–3-fold in HIV/MDR-TB co-infected patients.•Nevirapine does not show a relevant effect on bedaquiline and M2 exposure in HIV/MDR-TB co-infected patients.•Prior pharmacokinetic models were able to predict observed drug interactions in HIV/MDR-TB co-infected patients.•To normalise bedaquiline exposure during co-administration with LPV/r, an adjusted bedaquiline dosing regimen is proposed.

查看译文

关键词

Bedaquiline,Nevirapine,Ritonavir-boosted lopinavir,Population pharmacokinetic modelling,Drug–drug interactions,Prior information

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要